BFC Planning’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.9M Buy
14,572
+926
+7% +$1.09M 0.66% 24
2026
Q2
$16.4M Buy
13,646
+3,131
+30% +$3.2M 0.67% 21
2026
Q1
$9.7M Buy
10,515
+191
+2% +$194K 0.43% 41
2025
Q4
$11.1M Buy
10,324
+4,903
+90% +$4.69M 0.49% 36
2025
Q3
$4.14M Buy
5,421
+267
+5% +$199K 0.3% 64
2025
Q2
$4.02M Buy
5,154
+244
+5% +$190K 0.32% 60
2025
Q1
$4.06M Sell
4,910
-206
-4% -$171K 0.36% 57
2024
Q4
$3.95M Buy
5,116
+64
+1% +$53K 0.33% 58
2024
Q3
$4.48M Buy
+5,052
New +$4.54M 0.39% 53

Other funds holding LLY

BFC Planning's LLY Position: Q3 2026 in Review

BFC Planning increased its Eli Lilly (LLY) stake by 6.8% in Q3 2026, buying an estimated $1.09M and bringing the position to 14,572 shares worth $16.9M. The position accounts for 0.66% of the portfolio, ranked #24.

BFC Planning first reported a position in LLY in Q3 2024 and has held it in 9 quarters since. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • BFC Planning held 14,572 shares of Eli Lilly worth $16.9M as of Q3 2026.
  • BFC Planning bought 926 Eli Lilly shares in Q3 2026, an estimated $1.09M.
  • Eli Lilly made up 0.66% of BFC Planning's portfolio in Q3 2026, its #24 holding.
  • BFC Planning first reported a position in Eli Lilly in Q3 2024 and has held it in 9 quarters since.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.